Prevalence and Trajectory of COVID-19-Associated Hypercoagulability Using Serial Thromboelastography in a South African Population
Table 1
Changes in the TEG and anti-Xa levels between admission and at day 10/resolution.
TEG CKH
T1
T2
T3
n
Median (IQR)
n
Median (IQR)
n
Median (IQR)
Hypercoagulable
LY30-CK (%)
22
0 [0–0.1]
20
0 [0–0]
16
0 [0–0]
TEG-ACT (sec]
22
83.2 [78.5–87.9]
20
92.6 [78.5–106.6]
16
92.6 [73.9–106.6]
R-time
22
4.6 [4–5.2]
20
5 [4.6–6.2]
16
4.5 [3.7–6]
K-time
22
0.8 [0.8–1.0]
20
0.8 [0.8-0.9]
16
0.8 [0.8–1.1]
α angle
22
78.2 [76.9–79]
20
79.4 [77.6-81.1]
16
77.5 [75.6–79.7]
MA
22
69.5 [68.8–70.4]
20
70.3 [68.7-71.8]
16
70 [68.9-72.3]
Non-hypercoagulable
LY30-CK (%]
19
0 [0–0]
17
0 [0–0]
9
0 [0–0]
TEG-ACT (sec]
19
97.3 [78.5–116]
18
97.3 [87.9–116]
9
97.3 [87.9–106.6]
R-time
19
4.6 [3.5–5.3]
18
5.4 [4.9–6.1]
9
4.7 [4.3–5.9]
K-time
19
1 [0.8–1.8]
18
1.3 [1-1.6]
9
1 [0.8–1.3]
α-Angle
19
75.4 [69.9–77.5]
18
72.8 [71.5-76.9]
9
77.1 [72.7–79.7]
MA
19
65.3 [53.4–68.9]
18
64 [58-65.7]
9
65.6 [61.6-68.6]
Statistically significant. Data are expressed as median (interquartile range). T1 (admission), T2 (48 hours), T3 (resolution of hypoxia/day 10), TEG thromboelastography, ACT activated clotting time, CKH citrated kaolin heparinase, R reaction, K kinetics, MA maximum amplitude, LY30 lysis at 30 minutes.
